We have continued our work with Nuclera, advising on its additional US$12 million Series C funding to advance antibody engineering
The US$12 million financing extension led by Elevage Medical Technologies and Jonathan Milner, and joined by other existing investors British Business Bank and GK Goh, has brought Nuclera's total Series C funding to US$87 million.
The investment will accelerate the integration of antibody-specific capabilities into the Nuclera’s eProtein Discovery benchtop system, which enables multiplex protein screening, characterization, and expression in-house. This represents a strategic step as Nuclera moves into AI-enabled antibody engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models in biologics discovery.
Commenting on the transaction, Corporate Partner Ross McNaughton said: "It is no surprise that Nuclera's technology and pioneering research has generated such interest and we were very pleased to once again be able to assist them as they continue to develop as one of the UK's life sciences success stories. Nuclera has proved itself as one of the most promising life sciences companies in the UK ecosystem, and I've no doubt this extra funding will see them scale new heights by advancing its eProtein Discovery capabilities. I look forward to working with them as they continue to grow and succeed."
Dr Michael Chen, CEO and Co-Founder, Nuclera, said: “This financing underscores our growing momentum and demonstrates that we are expanding eProtein Discovery into one of the fastest-growing segments of biologics R&D. Thank you to the Taylor Wessing team for their continued support and for always being our trusted advisor in our growth journey. The firm's life sciences expertise is what attracted us to the team, and their advice that demonstrates their acute commercial understanding of our business as well as the subsequent successful results are what makes us keep coming back to them."
Our team consisted of Ross McNaughton (Partner) and Oli Denne (Senior Associate) in the Corporate team.
